Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron in Young Children With Neurogenic Detrusor Overactivity
NCT05621616Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Feb 2024
- Primary completion
- Feb 2026
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of mirabegron in neurogenic detrusor overactivity (NDO), sponsored by Astellas Pharma. Primary endpoint: Maximum Cystometric Capacity at Week 24. Started Feb 2024; status: completed.
02
Drugs
mirabegron
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT05621616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05621616.